Lipoprotein(a) and cardiovascular disease: prediction, attributable risk fraction, and estimating benefits from novel interventions.

MLA

Welsh, Paul, et al. “Lipoprotein(a) and Cardiovascular Disease: Prediction, Attributable Risk Fraction, and Estimating Benefits from Novel Interventions.” European Journal of Preventive Cardiology, vol. 28, no. 18, Dec. 2021, pp. 1991–2000. EBSCOhost, https://doi.org/10.1093/eurjpc/zwaa063.

APA

Welsh, P., Welsh, C., Celis-Morales, C. A., Brown, R., Ho, F. K., Ferguson, L. D., Mark, P. B., Lewsey, J., Gray, S. R., Lyall, D. M., Gill, J. M. R., Pell, J. P., Lemos, J. A. de, Willeit, P., & Sattar, N. (2021). Lipoprotein(a) and cardiovascular disease: prediction, attributable risk fraction, and estimating benefits from novel interventions. European Journal of Preventive Cardiology, 28(18), 1991–2000. https://doi.org/10.1093/eurjpc/zwaa063

Chicago

Welsh, Paul, Claire Welsh, Carlos A Celis-Morales, Rosemary Brown, Frederick K Ho, Lyn D Ferguson, Patrick B Mark, et al. 2021. “Lipoprotein(a) and Cardiovascular Disease: Prediction, Attributable Risk Fraction, and Estimating Benefits from Novel Interventions.” European Journal of Preventive Cardiology 28 (18): 1991–2000. doi:10.1093/eurjpc/zwaa063.